Experience in the treatment of patients with pulmonary embolism using apixaban and ultrasound inhalations of unfractionated heparin
Open Access
- 3 May 2023
- journal article
- research article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 28-34
Abstract
Introduction. Pulmonary embolism (PE) is one of the leading causes of death even in hospitalized patients. The standard treatment results are disappointing. Since 2004, we have tested a new method for the treatment of hemodynamically insignificant PE (own patent RU2224525C1) by using unfractionated heparin (UFH) in ultrasound inhalations with a nebulizer, since 2014 – in combination with apixaban. Aim. To improve the treatment of PE. Materials and methods. The hospital mortality rate of 713 patients of the cardiac intensive care unit with hemodynamically insignificant PE (from January 1, 2002 to December 31, 2017) was studied. Since 2004, patients have received ultrasound UFH (5000 units twice a day). Since 2014, nebulased UFH has been supplemented with the use of apixaban (10 mg twice a day for 7 days and 5 mg twice a day thereafter). Results and discussion. There is a distinct tendency to the PE hospital mortality decrease, coinciding with the nebulased UFH use (illustrated by a diagram). Neither the systemic bleeding nor the heparin-induced thrombocytopenia were observed. Clinical cases show first reduction of perfusion disorders are seeing scintigraphicaly in 7 days. Unlike LMWH UFH is recommended in severe kidney damage and obesity, thus ultrasound technique has advantages in such patients. Conclusions. Nebulased UFH is an available, simple, safe and effective in treatmtnt of hemodynamically insignificant PE, especially with the use of apixaban. A real improvement in lung perfusion takes 1 week, as shown scintigraphically.Keywords
This publication has 18 references indexed in Scilit:
- Nebulized anticoagulants in lung injury in critically ill patients—an updated systematic review of preclinical and clinical studiesAnnals of Translational Medicine, 2017
- Inhaled Heparin: Therapeutic Efficacy and Recent FormulationsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2017
- Erratum to “Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group” Journal of Critical Care 34 (2016) 95–102Journal of Critical Care, 2016
- Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-AnalysisPLOS ONE, 2016
- A Trial of Nebulised Heparin to Limit Lung Injury following Cardiac SurgeryAnaesthesia and Intensive Care, 2016
- 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolismEuropean Heart Journal, 2014
- Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trialCritical Care, 2010
- Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injuryCritical Care, 2010
- Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary EmbolismCirculation, 2004
- Effect of inhaled heparin on lung function and coagulation in healthy volunteersEuropean Respiratory Journal, 2002